Generic Name and Formulations:
Metaxalone 800mg; scored tabs.
King Pharmaceuticals, Inc.
Indications for SKELAXIN:
As adjunct treatment for acute, painful musculoskeletal conditions.
800mg 3–4 times daily.
≤12yrs: not established.
Anemias. Significant renal or hepatic dysfunction.
Renal or hepatic impairment (monitor LFTs). Elderly. Pregnancy, nursing mothers: not recommended.
Muscle relaxant (central).
Increased risk of sedation, respiratory depression with concomitant other CNS depressants (eg, alcohol, benzodiazepines, opioids, TCAs); monitor closely. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, opioids, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Concomitant with food may enhance CNS depression. May cause false (+) Benedict's test.
Drowsiness, dizziness, headache, nervousness, GI upset, rash, jaundice, hemolytic anemia, leukopenia; hypersensitivity reactions.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D